Literature DB >> 7858926

Empirical therapy for bacterial infections in neutropenic patients.

J Klastersky1.   

Abstract

Infection in neutropenic patients remains a continuing challenge as the modalities of cancer treatment evolve and new pathogens appear. Although the concept of empirical therapy remains valid, there is a need for adaptation of our therapeutic approaches to new clinical and microbiological evidence.

Entities:  

Mesh：

Substances：

Year:  1994        PMID： 7858926     DOI： 10.1007/bf00344047

Source DB:  PubMed          Journal:  Support Care Cancer        ISSN： 0941-4355            Impact factor:   3.603


  33 in total

Review 1.  From the Immunocompromised Host Society. The design, analysis, and reporting of clinical trials on the empirical antibiotic management of the neutropenic patient. Report of a consensus panel.

Authors: 
Journal:  J Infect Dis       Date:  1990-03       Impact factor: 5.226

2.  Three antibiotic regimens in the treatment of infection in febrile granulocytopenic patients with cancer. The EORTC international antimicrobial therapy project group.

Authors:  S C Schimpff; H Gaya; J Klastersky; M H Tattersall; S H Zinner
Journal:  J Infect Dis       Date:  1978-01       Impact factor: 5.226

3.  Vancomycin added to empirical combination antibiotic therapy for fever in granulocytopenic cancer patients. European Organization for Research and Treatment of Cancer (EORTC) International Antimicrobial Therapy Cooperative Group and the National Cancer Institute of Canada-Clinical Trials Group.

Authors: 
Journal:  J Infect Dis       Date:  1991-05       Impact factor: 5.226

4.  Streptococcal and enterococcal bacteremia in patients with cancer.

Authors:  A Awada; P van der Auwera; F Meunier; D Daneau; J Klastersky
Journal:  Clin Infect Dis       Date:  1992-07       Impact factor: 9.079

5.  Outpatient treatment of febrile episodes in low-risk neutropenic patients with cancer.

Authors:  E B Rubenstein; K Rolston; R S Benjamin; J Loewy; C Escalante; E Manzullo; P Hughes; B Moreland; A Fender; K Kennedy
Journal:  Cancer       Date:  1993-06-01       Impact factor: 6.860

6.  Aztreonam therapy in neutropenic patients with cancer.

Authors:  P G Jones; K V Rolston; V Fainstein; L Elting; R S Walters; G P Bodey
Journal:  Am J Med       Date:  1986-08       Impact factor: 4.965

7.  A comparison of imipenem to ceftazidime with or without amikacin as empiric therapy in febrile neutropenic patients.

Authors:  K V Rolston; P Berkey; G P Bodey; E J Anaissie; N M Khardori; J H Joshi; M J Keating; F A Holmes; F F Cabanillas; L Elting
Journal:  Arch Intern Med       Date:  1992-02

8.  Ceftazidime combined with a short or long course of amikacin for empirical therapy of gram-negative bacteremia in cancer patients with granulocytopenia.

Authors:  Thierry Calandra; J Klastersky; H Gaya; M P Glauser; F Meunier; S H Zinner
Journal:  N Engl J Med       Date:  1987-12-31       Impact factor: 91.245

9.  Acyclovir prophylaxis of herpes-simplex-virus infections.

Authors:  R Saral; W H Burns; O L Laskin; G W Santos; P S Lietman
Journal:  N Engl J Med       Date:  1981-07-09       Impact factor: 91.245

10.  Empiric antifungal therapy in febrile granulocytopenic patients. EORTC International Antimicrobial Therapy Cooperative Group.

Authors: 
Journal:  Am J Med       Date:  1989-06       Impact factor: 4.965
View more
  3 in total

Review 1.  Clinical and economic considerations of empirical antibacterial therapy of febrile neutropenia in cancer.

Authors:  G Dranitsaris
Journal:  Pharmacoeconomics       Date:  1999-10       Impact factor: 4.981

2.  Infectious complications of combination anticancer chemotherapy for urogenital cancers.

Authors:  T Matsumoto; K Takahashi; M Tanaka; J Kumazawa
Journal:  Int Urol Nephrol       Date:  1999       Impact factor: 2.370

3.  Ceftriaxone/Amikacin vs Ceftazidime/Amikacin as Empirical Therapy for Fever in Patients with Haematological Malignancy and Severe Granulocytopenia: Clinical and Economic Outcomes.

Authors:  F Rossini; P Pioltelli; S Bolis; L Borin; I Casaroli; E Lanzi; P Maffè; M Parma; P Tripputi; E M Pogliani
Journal:  Clin Drug Investig       Date:  1998       Impact factor: 2.859
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.